Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) Invested Capital (2020 - 2025)

Historic Invested Capital for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $144.0 million.

  • TScan Therapeutics' Invested Capital fell 3713.26% to $144.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $144.0 million, marking a year-over-year decrease of 3713.26%. This contributed to the annual value of $241.0 million for FY2024, which is 5625.69% up from last year.
  • Latest data reveals that TScan Therapeutics reported Invested Capital of $144.0 million as of Q3 2025, which was down 3713.26% from $176.7 million recorded in Q2 2025.
  • TScan Therapeutics' Invested Capital's 5-year high stood at $265.6 million during Q2 2024, with a 5-year trough of -$60.0 million in Q2 2021.
  • Its 5-year average for Invested Capital is $142.5 million, with a median of $154.2 million in 2023.
  • As far as peak fluctuations go, TScan Therapeutics' Invested Capital skyrocketed by 47863.97% in 2021, and later plummeted by 4645.08% in 2023.
  • Quarter analysis of 5 years shows TScan Therapeutics' Invested Capital stood at $160.8 million in 2021, then tumbled by 38.15% to $99.4 million in 2022, then surged by 55.09% to $154.2 million in 2023, then soared by 56.26% to $241.0 million in 2024, then crashed by 40.23% to $144.0 million in 2025.
  • Its last three reported values are $144.0 million in Q3 2025, $176.7 million for Q2 2025, and $210.2 million during Q1 2025.